BioSpace News Archive

Business

Sanofi Plans Spin-Off of Consumer Business, Lowers Profit Outlook

The French drugmaker’s shares dropped more than 15% Friday morning on the announcement that it has abandoned its goal of a 32% operating profit margin for 2025, focusing on long-term profitability.

October 27, 2023
·
2 min read
·
Kate Goodwin
Business

Merck Touts Strong Growth in Keytruda Sales, ADC Business in Q3

The company’s blockbuster cancer asset Keytruda brought in more than $6.3 billion in the third quarter, a 17% increase from the same period last year, while bolstering its antibody-drug conjugate portfolio.

October 27, 2023
·
2 min read
·
Tristan Manalac
FDA

FDA Approves Novel Corticosteroid Treatment Option for DMD Patients

Santhera Pharmaceuticals and partner Catalyst Pharmaceuticals got the FDA’s greenlight for their Duchenne muscular dystrophy drug Agamree, which is expected to launch in the first quarter of 2024.

October 27, 2023
·
2 min read
·
Tristan Manalac
FDA

Lilly’s Ulcerative Colitis Therapy Mirikizumab Finally Snags FDA Approval

Following an FDA rejection and a previous discontinuation in psoriasis, Eli Lilly’s anti-IL-23 antibody has finally won an approval in ulcerative colitis, joining a crowded inflammatory bowel disease market.

October 27, 2023
·
2 min read
·
Tristan Manalac
Business

Tricks and Treats as Biopharma’s Q3 Earnings Season Gets Underway

Merck and Novartis beat expectations this week with solid third-quarter financial results, while BMS, Sanofi and Takeda spooked investors with negative near- and mid-term projections.

October 27, 2023
·
2 min read
·
Greg Slabodkin
Policy

Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy

Everest Medicines announced that the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China, has approved its New Drug Application for Nefecon® for the treatment of primary immunoglobulin A nephropathy in adults at risk of disease progression.

October 27, 2023
·
5 min read
Policy

FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration has approved Vabysmo® for the treatment of macular edema following retinal vein occlusion.

October 27, 2023
·
8 min read
Business

Medivir AB - Interim Report January - September 2023

Updated data show that the combination fostrox + Lenvima® provides improved clinical efficacy compared to Lenvima study data alone in second-line HCC

October 27, 2023
·
7 min read
Job Trends

Press Release: Sanofi Enters Next Chapter of Play to Win Strategy

Sanofi provided a comprehensive update regarding its Play to Win strategy.

October 27, 2023
·
12 min read
Policy

New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy

Calliditas Therapeutics AB announced that its commercial partner Everest Medicines received approval from the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China.

October 27, 2023
·
1 min read